Page last updated: 2024-12-06

alniditan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alniditan: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID66004
CHEMBL ID88240
SCHEMBL ID717887
MeSH IDM0264501

Synonyms (24)

Synonym
CHEMBL88240
gtpl120
[3h]alniditan
gtpl117
n-[[(2r)-chroman-2-yl]methyl]-n'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine
PDSP2_001383
alniditan
PDSP1_001399
n-[[(2r)-3,4-dihydro-2h-chromen-2-yl]methyl]-n'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine
2-((3-(((r)-2-chromanylmethyl)amino)propyl)amino)-1,4,5,6-tetrahydropyrimidine
alniditan [inn:ban]
b57z82eoge ,
152317-89-0
unii-b57z82eoge
bdbm50403503
(-)-2-((3-(((r)-2-chromanylmethyl)amino)propyl)amino)-1,4,5,6-tetrahydropyrimidine
1,3-propanediamine, n-((3,4-dihydro-2h-1-benzopyran-2-yl)methyl)-n'-(1,4,5,6-tetrahydro-2-pyrimidinyl)-, (r)-
alniditan [inn]
SCHEMBL717887
HY-101698
CS-6739
Q4734060
DTXSID20870005
AKOS040741091

Research Excerpts

Overview

Alniditan is a new 5HT1D receptor agonist, belonging to a different chemical class from sumatriptan and other indole derivatives.

ExcerptReferenceRelevance
"Alniditan is a new migraine-abortive agent. "( Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
Gommeren, W; Haegeman, G; Heylen, L; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van de Weyer, I; Van Gompel, P; Vanhoenacker, P; Wouters, R, 1996
)
3.18
"Alniditan is a new 5HT1D receptor agonist, belonging to a different chemical class from sumatriptan and other indole derivatives used or being developed for the treatment of acute migraine. "( Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Subcutaneous Alniditan Study Group.
Dahlöf, CG; Diener, HC; Goldstein, J; Olesen, J; Schellens, R; Senard, JM; Simard, D; Steiner, TJ, 1996
)
3.18

Toxicity

ExcerptReferenceRelevance
"8 mg group is due to the termination of this trial arm after the incidence of a serious adverse event and a subsequent protocol amendment."( The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial.
Dahlöf, C; de Beukelaar, F; Diener, HC; Ferrari, MD; Mathew, N; Olesen, J; Tfelt-Hansen, P, 2001
)
0.6

Pharmacokinetics

ExcerptReferenceRelevance
"To compare the pharmacokinetic profile of intranasal alniditan during and outside migraine attacks, and to investigate the relationship between initial rise of alniditan plasma concentration, and headache improvement."( Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks.
de Beukelaar, F; Ferrari, MD; Roon, KI; Soons, PA; Uitendaal, MP, 1999
)
0.85
" Maximal plasma concentrations (Cmax), time to Cmax (tmax), and the area under the curve over 2 h (AUC(0,2 h)), were calculated from the individual plasma concentration-time profile, obtained from 10 blood samples in each patient, during each of the two administrations."( Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks.
de Beukelaar, F; Ferrari, MD; Roon, KI; Soons, PA; Uitendaal, MP, 1999
)
0.6
" All investigated pharmacokinetic parameters (Cmax, tmax, AUC(0,2 h)) were similar during and outside migraine attacks, both in the 2 mg (n = 13) and the 4 mg group (n = 14)."( Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks.
de Beukelaar, F; Ferrari, MD; Roon, KI; Soons, PA; Uitendaal, MP, 1999
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)1996Molecular pharmacology, Dec, Volume: 50, Issue:6
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1998British journal of pharmacology, Apr, Volume: 123, Issue:8
Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1996Molecular pharmacology, Dec, Volume: 50, Issue:6
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)1998British journal of pharmacology, Apr, Volume: 123, Issue:8
Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (75.00)18.2507
2000's4 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.44 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]